(Q50539422)

15 March 2018

title

Neuroendocrine response to antipsychotics: effects of drug type and gender. (English)

1 reference

15 March 2018

author name string

Gründer G

1

1 reference

15 March 2018

Wetzel H

2

1 reference

15 March 2018

Schlösser R

3

1 reference

15 March 2018

Anghelescu I

4

1 reference

15 March 2018

Hillert A

5

1 reference

15 March 2018

Lange K

6

1 reference

15 March 2018

Hiemke C

7

1 reference

15 March 2018

Benkert O

8

1 reference

15 March 2018

language of work or name

English

0 references

publication date

1 January 1999

1 reference

15 March 2018

published in

Biological Psychiatry

1 reference

15 March 2018

volume

45

1 reference

15 March 2018

issue

1

1 reference

15 March 2018

page(s)

89-97

1 reference

15 March 2018

Synthetic thyrotropin-releasing hormone. A potent stimulator of thyrotropin secretion in man

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Gender and the course of schizophrenia: differences in treated outcomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Dopaminergic regulation of growth hormone (GH) secretion in normal man: correlation of L-dopa and dopamine levels with the GH response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Regulation of thyrotrophin secretion by negative feedback of tri-iodothyronine on the hypothalamus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Dopamine infusion acutely inhibits the TSH and prolactin response to TRH

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Treatment of negative symptoms in schizophrenia with amisulpride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Differential effects of a dopaminergic drug (piribedil) on pituitary hormone release in normal men and women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Prolactin Responses to Neuroleptics in Normal and Schizophrenic Subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

The neuroendocrinological profile of roxindole, a dopamine autoreceptor agonist, in schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Basic biology of clozapine: electrophysiological and neuroendocrinological studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Time Course for Effects of Sulpiride and Chlorpromazine on Monoamine Metabolite and Prolactin Levels in Cerebrospinal Fluid from Schizophrenic Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Mechanism of Thyroid Hormone Inhibition of Thyrotropin-Releasing Hormone Action*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Effect of substituted benzamides on prolactin secretion in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Effect of methysergide and pimozide on apomorphine-induced growth hormone secretion in men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Dopaminergic inhibition of growth hormone and prolactin release during continuous in vitro perifusion of normal and adenomatous human pituitary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Neuroendocrine Control of Prolactin Secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Haloperidol plasma levels and clinical response in paranoid schizophrenics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Growth hormone and prolactin release after injection of thyrotropin-releasing hormone in patients with depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

The Effect of Neuroleptics on Serum Prolactin in Schizophrenic Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Studies of prolactin and TSH secretion by continuous infusion of small amounts of thyrotropin-releasing hormone (TRH).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Potent Antidopaminergic Activity of Estradiol at the Pituitary Level on Prolactin Release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Gender differences in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Effect of estradiol-17 beta on preprolactin messenger ribonucleic acid activity in the rat pituitary gland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Ratio of serum prolactin to haloperidol and early clinical outcome in acute psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Neuroendocrine pharmacology of serotonergic (5-HT) neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Neuroendocrine responses to single oral doses of remoxipride and sulpiride in healthy female and male volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Implications of normal brain development for the pathogenesis of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

An open clinical and biochemical study of ritanserin in acute patients with schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900125-5

10.1016/S0006-3223(98)00125-5

7 January 2021

Identifiers

DOI

1 reference

15 March 2018

1 reference

15 March 2018